CA2591917C - Methode de traitement des etats douloureux de la region anale et compositions correspondantes - Google Patents

Methode de traitement des etats douloureux de la region anale et compositions correspondantes Download PDF

Info

Publication number: CA2591917C
Authority: CA; Canada
Prior art keywords: anal; pain; nitroglycerin; sucralfate; adrenergic
Prior art date: 1998-02-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002591917A

Other languages

English (en)

Other versions

CA2591917A1 (fr

Inventor

Barry S. Fogel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Synchroneuron Inc

Original Assignee

Synchroneuron Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-27

Filing date

1999-02-25

Publication date

2009-05-19

1998-02-27 Priority claimed from US09/031,858 external-priority patent/US6159944A/en

1999-02-25 Application filed by Synchroneuron Inc filed Critical Synchroneuron Inc

1999-02-25 Priority claimed from CA002322168A external-priority patent/CA2322168C/fr

1999-09-02 Publication of CA2591917A1 publication Critical patent/CA2591917A1/fr

2009-05-19 Application granted granted Critical

2009-05-19 Publication of CA2591917C publication Critical patent/CA2591917C/fr

2019-02-25 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 105
230000000202 analgesic effect Effects 0.000 title claims abstract description 36
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims abstract description 85
239000000006 Nitroglycerin Substances 0.000 claims abstract description 73
229960003711 glyceryl trinitrate Drugs 0.000 claims abstract description 73
229960004291 sucralfate Drugs 0.000 claims abstract description 71
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims abstract description 68
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 46
229960004194 lidocaine Drugs 0.000 claims abstract description 43
206010002153 Anal fissure Diseases 0.000 claims abstract description 40
208000016583 Anus disease Diseases 0.000 claims abstract description 38
208000009531 Fissure in Ano Diseases 0.000 claims abstract description 36
208000014617 hemorrhoid Diseases 0.000 claims abstract description 19
235000019271 petrolatum Nutrition 0.000 claims abstract description 16
239000004264 Petrolatum Substances 0.000 claims abstract description 15
229940066842 petrolatum Drugs 0.000 claims abstract description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
239000000314 lubricant Substances 0.000 claims abstract description 13
238000011282 treatment Methods 0.000 claims description 57
239000006071 cream Substances 0.000 claims description 52
239000003814 drug Substances 0.000 claims description 26
239000002674 ointment Substances 0.000 claims description 22
206010036772 Proctalgia Diseases 0.000 abstract description 26
230000001684 chronic effect Effects 0.000 abstract description 6
208000002193 Pain Diseases 0.000 description 86
230000036407 pain Effects 0.000 description 82
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical group COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 74
239000000674 adrenergic antagonist Substances 0.000 description 71
229960002504 capsaicin Drugs 0.000 description 36
235000017663 capsaicin Nutrition 0.000 description 36
210000005072 internal anal sphincter Anatomy 0.000 description 32
230000000694 effects Effects 0.000 description 30
239000004615 ingredient Substances 0.000 description 28
239000003589 local anesthetic agent Substances 0.000 description 28
150000001875 compounds Chemical class 0.000 description 23
210000005070 sphincter Anatomy 0.000 description 22
208000005392 Spasm Diseases 0.000 description 18
206010019233 Headaches Diseases 0.000 description 17
239000004480 active ingredient Substances 0.000 description 17
229940079593 drug Drugs 0.000 description 17
231100000869 headache Toxicity 0.000 description 16
230000000699 topical effect Effects 0.000 description 16
241000282414 Homo sapiens Species 0.000 description 13
239000013543 active substance Substances 0.000 description 13
229960001389 doxazosin Drugs 0.000 description 13
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
208000024891 symptom Diseases 0.000 description 11
208000015815 Rectal disease Diseases 0.000 description 10
230000035876 healing Effects 0.000 description 10
210000004877 mucosa Anatomy 0.000 description 10
208000019751 Anorectal disease Diseases 0.000 description 9
239000005557 antagonist Substances 0.000 description 9
238000009472 formulation Methods 0.000 description 9
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
210000000664 rectum Anatomy 0.000 description 8
239000000829 suppository Substances 0.000 description 8
206010006784 Burning sensation Diseases 0.000 description 7
206010061218 Inflammation Diseases 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000004054 inflammatory process Effects 0.000 description 7
235000015110 jellies Nutrition 0.000 description 7
239000008274 jelly Substances 0.000 description 7
230000009471 action Effects 0.000 description 6
230000001464 adherent effect Effects 0.000 description 6
230000001800 adrenalinergic effect Effects 0.000 description 6
-1 antifungals Substances 0.000 description 6
210000001072 colon Anatomy 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 6
230000003000 nontoxic effect Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
230000002195 synergetic effect Effects 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 5
239000000048 adrenergic agonist Substances 0.000 description 5
230000003444 anaesthetic effect Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
229940126534 drug product Drugs 0.000 description 5
230000036541 health Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
108030001720 Bontoxilysin Proteins 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
229930064664 L-arginine Natural products 0.000 description 4
235000014852 L-arginine Nutrition 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
210000000436 anus Anatomy 0.000 description 4
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
229940053031 botulinum toxin Drugs 0.000 description 4
PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 4
230000008602 contraction Effects 0.000 description 4
230000002550 fecal effect Effects 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
229960000890 hydrocortisone Drugs 0.000 description 4
230000007794 irritation Effects 0.000 description 4
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
238000000034 method Methods 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
210000005036 nerve Anatomy 0.000 description 4
230000002688 persistence Effects 0.000 description 4
230000011514 reflex Effects 0.000 description 4
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
230000002889 sympathetic effect Effects 0.000 description 4
VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 4
229960001693 terazosin Drugs 0.000 description 4
239000002562 thickening agent Substances 0.000 description 4
239000005526 vasoconstrictor agent Substances 0.000 description 4
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
241000345998 Calamus manan Species 0.000 description 3
SYCBXBCPLUFJID-UHFFFAOYSA-N Pramoxine hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 SYCBXBCPLUFJID-UHFFFAOYSA-N 0.000 description 3
102100024304 Protachykinin-1 Human genes 0.000 description 3
101800003906 Substance P Proteins 0.000 description 3
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000000464 adrenergic agent Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
239000000556 agonist Substances 0.000 description 3
210000002255 anal canal Anatomy 0.000 description 3
230000008485 antagonism Effects 0.000 description 3
239000003026 cod liver oil Substances 0.000 description 3
235000012716 cod liver oil Nutrition 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
229960001259 diclofenac Drugs 0.000 description 3
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
229960002986 dinoprostone Drugs 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
208000002173 dizziness Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000005071 external anal sphincter Anatomy 0.000 description 3
229960005015 local anesthetics Drugs 0.000 description 3
239000002840 nitric oxide donor Substances 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
229940127240 opiate Drugs 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
229960001289 prazosin Drugs 0.000 description 3
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 3
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
235000012950 rattan cane Nutrition 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000000284 resting effect Effects 0.000 description 3
238000012552 review Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
239000011787 zinc oxide Substances 0.000 description 3
235000014692 zinc oxide Nutrition 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
239000005995 Aluminium silicate Substances 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
229940019097 EMLA Drugs 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
239000004166 Lanolin Substances 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
208000008469 Peptic Ulcer Diseases 0.000 description 2
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 2
208000004210 Pressure Ulcer Diseases 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
206010038080 Rectal ulcer Diseases 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
208000005298 acute pain Diseases 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
235000012211 aluminium silicate Nutrition 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000003502 anti-nociceptive effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
229940121357 antivirals Drugs 0.000 description 2
239000002249 anxiolytic agent Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
229960005274 benzocaine Drugs 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
229960003150 bupivacaine Drugs 0.000 description 2
229940105847 calamine Drugs 0.000 description 2
229960001747 cinchocaine Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000001839 endoscopy Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
229910052864 hemimorphite Inorganic materials 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
229960000201 isosorbide dinitrate Drugs 0.000 description 2
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
235000019388 lanolin Nutrition 0.000 description 2
229940039717 lanolin Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000005923 long-lasting effect Effects 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
229940075464 medicone Drugs 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
150000002823 nitrates Chemical class 0.000 description 2
230000003040 nociceptive effect Effects 0.000 description 2
239000000820 nonprescription drug Substances 0.000 description 2
229940038938 nupercainal Drugs 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
208000011906 peptic ulcer disease Diseases 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 description 2
229950007049 phenacaine Drugs 0.000 description 2
229960003418 phenoxybenzamine Drugs 0.000 description 2
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 2
229960001999 phentolamine Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000011552 rat model Methods 0.000 description 2
150000003902 salicylic acid esters Chemical class 0.000 description 2
229960000953 salsalate Drugs 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
229960001940 sulfasalazine Drugs 0.000 description 2
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000008719 thickening Effects 0.000 description 2
229940100611 topical cream Drugs 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229960005294 triamcinolone Drugs 0.000 description 2
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 2
RNWHGQJWIACOKP-UHFFFAOYSA-N zinc;oxygen(2-) Chemical compound [O-2].[Zn+2] RNWHGQJWIACOKP-UHFFFAOYSA-N 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
206010002112 Anal and rectal conditions Diseases 0.000 description 1
206010002180 Anal ulcer Diseases 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
208000035874 Excoriation Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000004454 Hyperalgesia Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
229940124091 Keratolytic Drugs 0.000 description 1
WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000029578 Muscle disease Diseases 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
206010031009 Oral pain Diseases 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
206010036783 Proctitis ulcerative Diseases 0.000 description 1
206010064993 Rectal fissure Diseases 0.000 description 1
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010040943 Skin Ulcer Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010043087 Tachyphylaxis Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
238000012084 abdominal surgery Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
239000003212 astringent agent Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229940035385 calmol Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
229940064332 cortef Drugs 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
230000013872 defecation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
229940075960 desitin Drugs 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
229940124645 emergency medicine Drugs 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
239000003906 humectant Substances 0.000 description 1
OWULVAZDMWJBLB-UHFFFAOYSA-N hydron;[2-(phenylcarbamoyloxy)-3-piperidin-1-ylpropyl] n-phenylcarbamate;chloride Chemical compound Cl.C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 OWULVAZDMWJBLB-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000030214 innervation Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007803 itching Effects 0.000 description 1
229960000829 kaolin Drugs 0.000 description 1
230000001530 keratinolytic effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000002988 lumbosacral plexus Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960005192 methoxamine Drugs 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940042472 mineral oil Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000001087 myotubule Anatomy 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
230000007383 nerve stimulation Effects 0.000 description 1
229960000965 nimesulide Drugs 0.000 description 1
HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
230000001129 nonadrenergic effect Effects 0.000 description 1
230000002536 noncholinergic effect Effects 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
230000037324 pain perception Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
229940118752 perifoam Drugs 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229940120090 pontocaine Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960001807 prilocaine Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
229950005741 rolipram Drugs 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000035807 sensation Effects 0.000 description 1
208000018316 severe headache Diseases 0.000 description 1
239000010686 shark liver oil Substances 0.000 description 1
229940069764 shark liver oil Drugs 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
231100000019 skin ulcer Toxicity 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
230000001148 spastic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
238000007464 sphincterotomy Methods 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002372 tetracaine Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
229960000317 yohimbine Drugs 0.000 description 1
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
229940112501 zostrix Drugs 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002591917A 1998-02-27 1999-02-25 Methode de traitement des etats douloureux de la region anale et compositions correspondantes Expired - Fee Related CA2591917C (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US09/031,858 US6159944A (en)	1998-02-27	1998-02-27	Method for treating painful conditions of the anal region and compositions therefor
US09/258,828 US6117877A (en)	1998-02-27	1999-02-25	Method for treating painful conditions of the anal region and compositions therefor
CA002322168A CA2322168C (fr)	1998-02-27	1999-02-25	Methode de traitement des etats douloureux de la region anale et compositions correspondantes
US09/258,828		1999-02-25
US09/031,858		1999-02-25

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002322168A Division CA2322168C (fr)	1998-02-27	1999-02-25	Methode de traitement des etats douloureux de la region anale et compositions correspondantes

Publications (2)

Publication Number	Publication Date
CA2591917A1 CA2591917A1 (fr)	1999-09-02
CA2591917C true CA2591917C (fr)	2009-05-19

Family

ID=38421303

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002591917A Expired - Fee Related CA2591917C (fr)	1998-02-27	1999-02-25	Methode de traitement des etats douloureux de la region anale et compositions correspondantes

Country Status (1)

Country	Link
CA (1)	CA2591917C (fr)

1999
- 1999-02-25 CA CA002591917A patent/CA2591917C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2591917A1 (fr)	1999-09-02

Legal Events

Date	Code	Title	Description
2007-05-31	EEER	Examination request
2011-02-25	MKLA	Lapsed

Publication	Publication Date	Title
US6117877A (en)	2000-09-12	Method for treating painful conditions of the anal region and compositions therefor
CA2322168C (fr)	2010-01-05	Methode de traitement des etats douloureux de la region anale et compositions correspondantes
US5504117A (en)	1996-04-02	Pharmacologic preparation for the treatment of anal disorders
CA2168247C (fr)	2000-12-12	Composition donneuse d'oxyde nitrique et procede de traitement de troubles anaux
US6987129B2 (en)	2006-01-17	Compounds and methods for the treatment of urogenital disorders
JP2000500449A (ja)	2000-01-18	一酸化二窒素を含む鎮痛剤、抗炎症剤、および抗発熱剤のための投与媒体とそれらの医薬組成物
US10391074B2 (en)	2019-08-27	Topical preparation for pain relief
CA2591917C (fr)	2009-05-19	Methode de traitement des etats douloureux de la region anale et compositions correspondantes
US20070105940A1 (en)	2007-05-10	Method for treating pain
MXPA00008336A (en)	2002-07-25	Method for treating painful conditions of the anal region and compositions therefor
US5962008A (en)	1999-10-05	Topical medicament for use in treatment of anorectal inflammation
US12295922B2 (en)	2025-05-13	Topical medicament for use in treatment of anorectal inflammation
US6693100B1 (en)	2004-02-17	Pharmaceutical compositions for treating psoriasis
RU2023444C1 (ru)	1994-11-30	Ранозаживляющее средство для местного применения
US20230057930A1 (en)	2023-02-23	Compositions for alleviating the symptoms of low anterior resection syndrome by topical administration to the neorectum
CA2384685A1 (fr)	2001-03-22	Compositions pharmaceutiques destinees au traitement du psoriasis
CA2009402A1 (fr)	1991-08-06	Utilisation de la benzydamine et de ses sels pour le soulagement de la douleur associee aux infections herpetiques et vaporisation au laser des condylomes
HK1032545B (en)	2008-01-11	Nitric oxide donor composition and method for treatment of anal disorders
AU2010227094A1 (en)	2010-11-04	Compounds and methods for the treatment of urogenital disorders